Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis

NCT05061693 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT05061693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05061693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Completed
Start date
November 4, 2021
Completion date
February 28, 2024
Enrollment
146 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

prurigo nodularis